Granules India to host Q1 FY27 earnings call on July 21

Granules India Limited will conduct an earnings conference call on July 21, 2026, to discuss its financial performance for the first quarter of FY27. The call is scheduled to begin at 5:00 PM IST and will provide insights into the company's business updates and operational results. This initiative allows analysts and investors to engage directly with the management regarding the quarterly outcomes.

The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The conference serves as a formal platform for the company to present its financial figures and strategic direction for the period. Specific dial-in numbers have been arranged for participants to join the discussion from various locations.

Key Participants

The earnings call will feature participation from senior leadership, including:

Dr. Krishna Prasad Chigurupati – Chairman & MD
Ms. Priyanka Chigurupati – Executive Director
Mr. Mukesh Surana – Chief Financial Officer
Dr. P.V. Srinivas – Chief Technology Officer
Mr. Sanjay Kumar – Chief Strategy Officer

Access Details

Participants can join the conference using the following access numbers:

Access Numbers	Details
Primary Number	+91 22 6280 1550
	+ 91 22 7115 8378
International Toll Free Number	Hong Kong: 800 964 448
	Singapore: 800 101 2045
	USA: 1866 746 2133
	UK: 0808 101 1573

RSVP for the event can be sent to Ms. Prachi Ambre at MUFG Intime India Pvt. Ltd., who is handling investor relations for the call.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.05%	-2.45%	+12.50%	+58.43%	+77.09%	+137.90%

Granules India has secured Sole First-to-File (FTF) status for its Abbreviated New Drug Application (ANDA) for Sodium Oxybate Extended-Release for Oral Suspension, the generic equivalent of LUMRYZ. This regulatory achievement marks the company's second Sole FTF ANDA, reinforcing its capabilities in complex generics for the U.S. market.

Regulatory Milestone

The approval for Sodium Oxybate Extended-Release for Oral Suspension highlights Granules India's strategic emphasis on complex and differentiated drug formulations. The product is indicated in the United States for the treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy.

Parameter	Details
Approval Type	Sole First-to-File (FTF) ANDA
Product	Sodium Oxybate Extended-Release for Oral Suspension
Therapeutic Indication	Cataplexy or excessive daytime sleepiness in narcolepsy
Reference Brand	LUMRYZ

Strategic Significance

This is Granules India's second Sole First-to-File ANDA, following its earlier success with Amphetamine Extended-Release Tablets. The FTF designation positions the company as a sole generic entrant during the exclusivity period, providing a competitive edge. Dr. Krishna Prasad Chigurupati, Chairman & Managing Director, stated that this achievement reflects the strength of the company's R&D and regulatory capabilities, reinforcing its commitment to building a differentiated portfolio.